Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Aanika Balaji"'
Autor:
Evan J Lipson, Jarushka Naidoo, Julie Brahmer, Ludmila Danilova, Elizabeth M Jaffee, Won Jin Ho, Mark Yarchoan, Maximilian F Konig, Yasser Ged, Jean Hoffman-Censits, Jennifer Durham, Laura Cappelli, Sanjay Bansal, Aanika Balaji, Rajat Mohindra, Stephanie L Alden, Tanguy Y Seiwert, Chester J Kao, Soren Charmsaz, Madalena Brancati, Howard L Li, Kabeer Munjal, Hua-Ling Tsai, Alexei Hernandez, Nicole Gross, Erin M Coyne, Sarah M Shin, Brian Christmas, Christopher Thoburn, Marina Barretti, Rachel Garonce-Hediger, Laura Tang, G Scott Chandler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/9ecf458f7da7428ea7c6e82123a0c044
Autor:
Sarah Kanbour, Aanika Balaji, Nicholas Maragakis, Nicholas Stanley Clarke, Nestoras Mathioudakis
Publikováno v:
Journal of Clinical and Translational Endocrinology Case Reports, Vol 28, Iss , Pp 100143- (2023)
Background: To describe the clinical manifestations, treatment, and prognosis of a patient with type 1 diabetes (T1D) and concurrent diagnoses of painful treatment-induced neuropathy of diabetes (TIND) and restless leg syndrome (RLS). Case report: A
Externí odkaz:
https://doaj.org/article/7a2d009845bb4d7c95836951b2cce255
Autor:
Aanika Balaji, Sarah Lou Clever
Publikováno v:
JMIR Medical Education, Vol 8, Iss 1, p e37401 (2022)
Externí odkaz:
https://doaj.org/article/a147a91a239d4323bcde27949ceb6c0d
Autor:
Jarushka Naidoo, Matthew Guo, Aanika Balaji, Joseph Murray, Joshua Reuss, Seema Mehta Steinke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/cbb8863ceb124706b74a92222c68d129
Autor:
Lei Zheng, Julie R Brahmer, Patrick M Forde, Jarushka Naidoo, Cheng Ting Lin, Peter B Illei, Sonye K Danoff, Karthik Suresh, Christine Hann, Aanika Balaji, Melinda Hsu, Josephine Feliciano, Kristen Marrone, Valerie Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Background Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management
Externí odkaz:
https://doaj.org/article/8744b96ba9a44fff9d9e0106c494995a
Publikováno v:
Journal of Clinical and Translational Science, Vol 4, Pp 73-73 (2020)
OBJECTIVES/GOALS: This study aims to assess the outcomes of a new virtual multidisciplinary immune-related toxicity (IR-tox) team implemented at Johns Hopkins Hospital. In particular, to understand if the IR-tox team’s input reduced the number of i
Externí odkaz:
https://doaj.org/article/d00f5ace3a3b4b0188bbbc3e79373034
Publikováno v:
Journal of Case Reports and Images in Oncology. 9:1-7
Introduction: Cholangiocarcinomas (CCA) are rare, aggressive tumors often diagnosed in advanced stages with limited evidence guiding therapy on progression. Case Report: We report a case of advanced CCA with rapid and aberrant progression, refractory
Autor:
Aanika Balaji, Sarah Clever
UNSTRUCTURED N/A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6002e43481a14d8467dd52d7bedf56f5
https://doi.org/10.2196/preprints.37401
https://doi.org/10.2196/preprints.37401
Autor:
Guy Ben-Betzalel, Wei Qiao, Justine V. Cohen, Sarah A. Weiss, Lisa Manuzzi, Ibraheim Hajir, Mark P. Lythgoe, Douglas B. Johnson, Sai Ching J. Yeung, David Faleck, Gal Markel, Michael Dougan, Dwight H. Owen, Jiajia Zhang, Giulia Costanza Leonardi, Mark M. Awad, Christina A. Arnold, Robin B. Mendelsohn, Hamzah Abu-Sbeih, MacLean C. Sellers, Giuseppe Lamberti, Nick Powell, Elad Sharon, Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, David J. Pinato, Yinghong Wang, Aanika Balaji
Publikováno v:
Journal of Clinical Oncology
Web of Science
Web of Science
PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who recei
Autor:
Won Jin Ho, Jacquelyn W. Zimmerman, Paz Vellanki, Jiajia Zhang, Deepti Venkatraman, Mark Yarchoan, Daniel A. Laheru, Ranee Mehra, Hany Elmariah, Kristen A. Marrone, Joshua E. Reuss, Khalid Hajjir, Beatriz Wills, Aanika Balaji, Jarushka Naidoo, Ross C. Donehower, Deborah K. Armstrong, Joseph Heng, Matthias Holdhoff
Publikováno v:
J Oncol Pract
PURPOSE: Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs). The proportion of patients who are hospitalized for irAEs and their spectrum, management, and outcomes are not well described. METHODS: We report the proportion